Abstract
During repair of connective tissue, resting fibroblasts become ‘activated’; that is, they migrate into the wound where they synthesize and remodel new extracellular matrix. The differentiated fibroblast responsible for this action is termed the myofibroblast, which expresses the highly contractile protein α—smooth muscle actin (α—SMA) and is responsible for the synthesis and remodeling of extracellular matrix (ECM). Persistence of the myofibroblast is a key characteristic of fibrotic diseases including scleroderma. Proteins such as transforming growth factorβ (TGFβ), endothelin-1 (ET- 1), connective tissue growth factor (CCN2/CTGF) and platelet derived growth factor (PDGF) are believed to contribute to myofibroblast differentiation and persistence. Moreover, it is now known that elevated adhesive and contractile signaling is a key feature of fibrotic fibroblasts. This review summarizes recent findings aimed at developing new, rationally-designed therapies for the fibrosis in scleroderma.
Current Enzyme Inhibition
Title: Sticking it to Scleroderma: Potential Therapies Blocking Elevated Adhesive and Contractile Signaling
Volume: 6 Issue: 2
Author(s): Andrew Leask
Affiliation:
Keywords: PDGF, TGFβ, endothelin, rac, PPARγ, PKCε
Abstract: During repair of connective tissue, resting fibroblasts become ‘activated’; that is, they migrate into the wound where they synthesize and remodel new extracellular matrix. The differentiated fibroblast responsible for this action is termed the myofibroblast, which expresses the highly contractile protein α—smooth muscle actin (α—SMA) and is responsible for the synthesis and remodeling of extracellular matrix (ECM). Persistence of the myofibroblast is a key characteristic of fibrotic diseases including scleroderma. Proteins such as transforming growth factorβ (TGFβ), endothelin-1 (ET- 1), connective tissue growth factor (CCN2/CTGF) and platelet derived growth factor (PDGF) are believed to contribute to myofibroblast differentiation and persistence. Moreover, it is now known that elevated adhesive and contractile signaling is a key feature of fibrotic fibroblasts. This review summarizes recent findings aimed at developing new, rationally-designed therapies for the fibrosis in scleroderma.
Export Options
About this article
Cite this article as:
Leask Andrew, Sticking it to Scleroderma: Potential Therapies Blocking Elevated Adhesive and Contractile Signaling, Current Enzyme Inhibition 2010; 6(2) . https://dx.doi.org/10.2174/157340810791232999
DOI https://dx.doi.org/10.2174/157340810791232999 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Development of Clinical Trial Assessments for the Study of Interstitial Lung Disease in Patients who have Connective Tissue Diseases-Methodological Considerations
Current Rheumatology Reviews The Clinical Spectrum, Diagnosis, Pathogenesis and Treatment of Hashimotos Encephalopathy (Recurrent Acute Disseminated Encephalomyelitis)
Current Medicinal Chemistry Fibrosis as a Therapeutic Target Post-Myocardial Infarction
Current Pharmaceutical Design Digital Ulcers in Systemic Sclerosis – Frequency, Subtype Distribution and Clinical Outcome
Current Rheumatology Reviews Gender Disparity in Pediatric Diseases
Current Molecular Medicine Th17 Cells: The Role in Immunity
Current Immunology Reviews (Discontinued) Diagnostic and Prognostic Potential of the Macrophage Specific Receptor CD163 in Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Review on Bosentan, A Dual Endothelin Receptor Antagonist for the Treatment of Pulmonary Arterial Hypertension
Recent Patents on Cardiovascular Drug Discovery Inflammation, High Density Lipoprotein and Endothelium
Current Medicinal Chemistry NTproBNP: An Important Biomarker in Cardiac Diseases
Current Topics in Medicinal Chemistry Beta-cell Management in Type 2 Diabetes: Beneficial Role of Nutraceuticals
Endocrine, Metabolic & Immune Disorders - Drug Targets Apo A-1 Mimetic Peptides as Atheroprotective Agents in Murine Models
Current Drug Targets Viral Anti-Inflammatory Reagents: The Potential for Treatment of Arthritic and Vasculitic Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets Sleep in Interstitial Lung Disease
Current Respiratory Medicine Reviews Rheumatic Manifestations in Malignancy
Current Rheumatology Reviews Hashimotos Thyroiditis: From Genes to the Disease
Current Genomics Strategies for Leukotriene Modulation in Dermatology: Even More Visionary Perspectives? An Update
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Autoimmunity and Apoptosis - Therapeutic Implications
Current Medicinal Chemistry Energetic Metabolic Roles in Pulmonary Arterial Hypertension and Right Ventricular Remodeling
Current Pharmaceutical Design Autoantibodies and Sjogren’s Syndrome: A Physiologist’s Perspective
Current Pharmaceutical Biotechnology